Funda Meric-Bernstam, MD, chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, discusses some of the key aspects of successful trials.
Funda Meric-Bernstam, MD, chair of the Department of Investigational Cancer Therapeutics and medical director of the Institute for Personalized Cancer Therapy at The University of Texas MD Anderson Cancer Center, discusses some of the key aspects of successful trials ahead of a discussion at the 2021 Cholangiocarcinoma Foundation Annual Conference. Meric-Bernstam is co-chair of the conference.
Transcript
You’re the moderator for a session on clinical trials in cholangiocarcinoma. What are some of the topics in that discussion you’re most excited to hear about?
Clinical trial enrollment is actually a very complicated aspect in many ways. It's important to think about how to design clinical trials. How do you conduct clinical trials, especially for rare diseases such as cholangiocarcinoma? How do you identify patients? How do you identify centers that can really meaningfully contribute? How do you make sure that everybody's aware of these trials? How do you make sure patients are willing to travel to centers that have trials ongoing, you know, which may not be right in their backyard? How do you make these trials patient friendly? How do you make it so that we can conduct them during, you know, complicated environments like this, when we have COVID and it adds extra challenges to transportation? As well as, for each individual patient, how do they pick a trial? What should they be looking for? How do they really understand what's being offered, and what is the lingo that we use every day, but really, maybe not at all clear? You know, what it is that we're saying?
Also, as a physician, how do we best identify the trial that's going to be most effective for the patient in front of us? Because ultimately, we want to make sure that for each individual patient we're giving the best treatment option and really to determine whether that's a clinical trial or if it's not a clinical trial. Of course, I always advocate for a clinical trial whenever feasible, but making sure that we are looking at the best option for each individual patient. And on the flip side, for each clinical trial, the trial is more likely to be informative if we're doing a better job at matching patients to the mechanism of action of the drugs and really being thoughtful about the microbiology of the tumor and the treatments we're offering. I think these are the many different areas that we're going to cover [this topic] both from a provider standpoint and from a patient consumer standpoint, as well as you're getting an industry perspective on this. So I'm very excited, and I think this is gonna be very fun.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More